Gilead Sciences News - May 2026
Gilead secures Hepcludex approval, first US hepatitis delta treatment
Gilead Sciences received accelerated FDA approval for Hepcludex on May 24, 2026. Hepcludex is the first and only treatment for chronic hepatitis delta virus in...
Gilead's first quarter 2026 revenue of $7.0B beat estimates, driven by 10% growth in its HIV franchise.
Gilead reported first quarter revenue of $7.0 billion and non-GAAP EPS of $2.03, beating analyst estimates. Results were driven by strong growth in the HIV and...
Gilead Sciences Inc Q1 2026 Earnings Preview: What Analysts Expect on May 07, 2026
Gilead Sciences is expected to report Q1 2026 revenue of $6.89 billion and EPS of $1.89, with its current stock price of $132.69 trading roughly 16% below the...